Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

• Status: Unknown status
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fengxi Su
• Treatments: Tamoxifen; Toremifene

Criteria

Inclusion Criteria:

• Clinical diagnosis of Breast cancer

• Received standard treatment (chemotherapy, operation, or radiotherapy)

• premenopausal

• estrogen and/or progesterone receptor positive

Exclusion Criteria:

• Metastatic tumors

• During pregnancy or lactation